MedPacto announced on the 22nd that it introduced its innovative drug candidate for bone diseases at the 35th Spring Scientific Conference of the Korean Society for Bone and Mineral Research, held from the 18th to the 20th at the Grand Walkerhill Hotel in Gwangjin-gu, Seoul.
On the last day of the conference, the 20th, MedPacto CEO Seongjin Kim introduced the innovative drug candidate for bone diseases, "MP2021," during a session titled "Latest Research on Bone Cell Biology." In his presentation, CEO Kim explained the mechanism of action and therapeutic effects of MP2021.
MP2021 is a new drug candidate targeting bone diseases and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoporosis. In human bone marrow, osteoclasts exist, and when osteoclasts differentiate into multinucleated osteoclasts, they resorb bone. This process is a major cause of bone diseases such as rheumatoid arthritis and osteoporosis. MP2021 is a drug candidate that inhibits the multinucleation of osteoclasts and suppresses bone resorption.
Unlike other treatments, MP2021 does not inhibit inflammation or growth factors of osteoclasts but prevents the formation of multinucleated osteoclasts that dissolve bone, according to the company. A MedPacto representative stated, "We recently completed animal testing for MP2021 and are conducting toxicity tests in Europe based on that. We have also completed the PCT (Patent Cooperation Treaty) international patent application for MP2021."
Meanwhile, the Korean Society for Bone and Mineral Research is an academic research organization aimed at contributing to medical advancement and public health promotion through research and academic exchange on musculoskeletal metabolic diseases, including osteoporosis. The spring scientific conference featured 70 presentations across 35 sessions, with invited scholars from around the world specializing in musculoskeletal diseases as well as domestic and international academic figures.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
